SCA
ADMA icon

Snowden Capital Advisors’s ADMA Biologics ADMA Stock Holding History

Snowden Capital Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,617
Closed -$194K – 1279
2025
Q4 		$194K Buy
+10,617
New +$179K 0.01% 1226

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Snowden Capital Advisors's ADMA Position: Q1 2026 in Review

Snowden Capital Advisors sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 10,617 shares — an estimated $194K sold.

Snowden Capital Advisors first reported a position in ADMA in Q4 2025 and held it in 1 quarter. The position peaked at $194K in Q4 2025. 357 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Snowden Capital Advisors reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Snowden Capital Advisors sold 10,617 ADMA Biologics shares in Q1 2026, an estimated $194K.
  • Snowden Capital Advisors first reported a position in ADMA Biologics in Q4 2025 and held it in 1 quarter.
  • Snowden Capital Advisors's ADMA Biologics position peaked at $194K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.